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Available online 30 June 2016Psoriasis is characterized by uncontrolled proliferation and poor differentiation. Sirtuin1 (SIRT1) a class III
deacetylase, crucial for differentiation in normal keratinocytes, is reduced in psoriasis. Down regulated SIRT1
levels may contribute to poor differentiation in psoriasis. In addition, the levels of early differentiation factors
Keratin1 (K1) and Keratin10 (K10) are depleted in psoriasis. We attempted to study a possible effect of fructose,
a SIRT1 upregulator and Propylthiouracil (PTU) to augment differentiation in psoriatic keratinocytes.
Keratinocytes were cultured from lesional biopsies obtained from psoriatic patients and control cells were ob-
tained from patients undergoing abdominoplasty. Cells were treated with fructose and PTU individually. K1
and K10 transcript levels were measured to evaluate early differentiation; SIRT1 protein expression was also
studied to decipher its role in the mechanism of differentiation. The K1, K10 transcript levels, SIRT1 protein
and transcript levels in fructose treated psoriatic keratinocyteswere improved. This suggests keratinocyte differ-
entiation was induced by fructose through SIRT1 upregulation. Whereas PTU induced differentiation, as con-
ﬁrmed by improved K1, K10 transcript levels followed a non-SIRT1 mechanism. We conclude that the use of
fructose and PTU may be an adjunct to the existing therapies for psoriasis.








A hallmark of lesional psoriatic skin is premature keratinocyte differ-
entiation and disturbed keratinization, altering the formation of corniﬁed
envelope in psoriasis. Human epidermal keratinocytes stratify into colo-
nies and cells in stratum granulosum, stratum lucidum and stratum
corneum gradually lose their mitotic potential to begin terminal differen-
tiation. Differentiation is a highly organized process wherein the proteins
K1, K10, proﬁlaggrin, involucrin, loricrin, and other proteins of corniﬁed
envelope are sequentially expressed [1].
There had been a debate about the progress of differentiation pat-
tern in psoriasis. Until 1992 it was thought that only the last step in dif-
ferentiationwas altered, however Bernerd et al. showed that alterations
are found from the ﬁrst stage itself [2]. The ﬁrst step of differentiation
involves heterodimerization of K1 and K10 to form cytoskeletaliation in poorly differentiated
logy, Rajalakshmi Engineering
yalan).
. This is an open access article underﬁlaments. This keratin pair is the most abundant protein in differentiat-
ed keratinocytes [3].
Keratin K1/K10 regulates keratinocyte growth in the epidermis
which is proved by in vitro experiments conducted by Paramio et al.
(2001) [4]. They reported that K10 is directly involved in cell cycle con-
trol which onsets keratinocyte differentiation. Interestingly several
other studies have shown that mutations either in K1/K10 or absence
of K10 showed greater epidermal proliferation in the basal layer and hy-
perkeratosis [5,6]. Furthermore in situ hybridization of K10 transcripts
proved a delayed keratin 10 synthesis in psoriatic epidermis [2]. These
studies markedly prove the essential role of K1/K10 in differentiation
and controlled proliferation. Many therapies in the past targeted differ-
entiation, in the same lines we were on the lookout for a differentiation
improving factor.
A study published by Blander et al. (2009) [7] exposed the potential
role of SIRT1 in inducing keratinocyte differentiation and inhibiting
keratinocyte proliferation. Elevated IFN gamma levels inhibits SIRT1
expression and sensitizes psoriatic keratinocytes to IL-22 mediated in-
ﬂammatory response altering epidermal differentiation [8]. Pillai and col-
league (2008) found that fructose augmented SIRT1 levels in heart [9].
Since SIRT1mediated effects are tissue speciﬁc, we attempted to increase
SIRT1 levels and improve differentiation in psoriatic keratinocytes, bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that PTU cleared lesions in psoriatic patients and improved differentiation
as conﬁrmed by modulated levels of involucrin [10,11]. In this study, we
have focused on the role of fructose and PTU to improve differentiation
in psoriatic keratinocytes and further explored the impact of these com-
pounds on SIRT1 levels, a promoter of keratinocyte differentiation.
2. Materials and methods
2.1. Recruitment of patients and collection of samples
Patients (N = 7) with chronic plaque psoriasis, but otherwise in
general good health who visited Saveetha Medical College Hospital,
Chennai, India participated in this study. Psoriasis was conﬁrmed by
Psoriasis Area Severity Index (PASI) score by a dermatologist. None of
the recruited patients had received any topical treatment for the last
2 weeks or any systemic treatment for the last 1 month. Skin from pa-
tients undergoing abdominoplasty served as control samples. Lesional
biopsy specimens (5 mm) were obtained through punch biopsy from
patientswith chronic plaque psoriasis. The studywas approved by Insti-
tutional Ethical Committee, Saveetha University (Chennai) and has
been performed in accordance with the ethical standards as laid down
in the 1964 Declaration of Helsinki and its later amendments or compa-
rable ethical standards. Informed consent was obtained from each par-
ticipant included in the study.
2.2. Primary culture
The biopsy specimens were incubated overnight in 0.3% dispase
(Sigma, USA) in Phosphate Buffered Saline (PBS) supplemented with
50 μg/ml Gentamicin (Life Technologies, USA) at 4 °C. After incubation
the dermis layer was mechanically removed and discarded, the epider-
mal layer was treated with 0.25% trypsin (Life Technologies, USA) at
37 °C for 30min. Cell dissociation was achieved by aspiration using Pas-
teur pipette followed by ﬁltration (70 μm cell strainer). Keratinocytes
Serum Free Medium (K-SFM) (Life Technologies, USA) was used to
wash ﬁltered keratinocytes. The viability of the cells was always N95%
as determined by Trypan blue exclusion test. To generate keratinocyte
cultures, suspension of primary epidermal cells (4 × 104 cells/cm2)
were plated in 100 mm petri dishes. The culture was supplemented
with keratinocytes supplements such as Epidermal Growth Factor
(EGF) 0.1 ng/ml, Bovine pituitary extract 25 μg/ml, and Gentamicin
50 μg/ml in K-SFM and the ﬂasks were maintained in a humidiﬁed at-
mosphere containing 5% CO2 at 37 °C. The medium was changed every
2 days and the third passage keratinocytes with 70–80% conﬂuence
was used for further experiments.
2.3. Cell proliferation assay
For analyzing cell proliferation via MTT assay, keratinocytes (1 × 104
cells/well) were incubated with different concentrations of PTU (2–
10 mM) and fructose (1–20 mM) for 24 h, 48 h and 72 h in 96 well
plates and were incubated at 37 °C in a humidiﬁed atmosphere with
5% CO2. Stock solutions of compounds were initially dissolved in
DMSO and further diluted with fresh complete medium. MTT reagent
(50 μl) (5 mg/ml in PBS), was added to each well and incubated at
37 °C for 4 h. At the end of the incubation period, the supernatant was
removed completely without disturbing the cell layer, 150 μl of DMSO
was added and read on a microplate reader at 570 nm.
2.4. RNA isolation and real-time polymerase chain reaction (RT-PCR)
TRIzol reagent (Life Technologies, USA) was used to extract total RNA
to be analyzed by real-time PCR. The expression of SIRT1, K1, K10 and β-
ActinmRNAwere evaluatedusing SYBRGreenPCR reagents following the
manufacturer's protocol on an Applied Biosystem Thermocycler. Theforward and reverse primers used in real-time PCR were as follows: For
SIRT1, forward: 5′-TCAGTGTCATGGTTCCTTTGC-3′; reverse: 5′-AATCTG
CTCCTTTGCCACTCT-3′, K1 forward 5′-ATTTCTGAGCTGAATCGTGTGATC-
3′ reverse 5′-CTGATGGACTGCTGCAAGTT-3′ K10 forward 5′-ATGAGCTG
ACCCTGACCAAG-3′ reverse 5′- TCACATCACCAGTGGACACA-3′ and for β-
Actin forward: 5′-AGGCACCAGGGCGTGAT-3′; reverse 5′- GCCCACATAG
GAATCCTTCTGAC-3′. The gene expression levels were determined by
normalizing to β-Actin mRNA expression. The values obtained are pre-
sented as mean ± SD.
2.5. Western blot
Solubilized protein samples (40 μg; measured and equalized in each
fraction using the Bio-Rad RC-DC protein assay; Bio-Rad) were separated
by SDS-PAGE and transferred onto PVDFmembrane (GE Healthcare, UK).
Membraneswere blockedwith 3% (w/v)milk protein in Tris-buffered sa-
line containing 0.1% Tween-20, and then incubated overnight with rabbit
polyclonal anti-SIRT1 antibody (sc-15404, 1:1000 dilution, Santa Cruz
Technologies, USA). Detection of bandswas achieved by using the chemi-
luminescent substrate Super Signal West Pico (Pierce, Rockford, IL, USA).
Blot is representative of three separate blots and densitometrywas deter-
mined. Reference protein measurements were made with rabbit poly-
clonal anti-β-actin primary antibody in a 3% (w/v) Tris-buffered saline
(1:1000 dilution, Santa Cruz Technologies, CA, USA).
2.6. Statistics
All values are represented asmean± S.D. of the threemeasurements.
A one-way analysis of variance test for post hoc multiple comparisons
was used to determine signiﬁcance. Probability values b0.05were consid-
ered signiﬁcant.
3. Results
MTT assay (Fig. 1A and B) shows percentage of live cells from con-
trol, untreated and treated psoriatic keratinocytes at 24 h, 48 h and
72 h. PTU treatment (2–10mM) and fructose treatment (1–20mM) de-
creased proliferation of psoriatic keratinocytes when compared to un-
treated cells. A dose of 4 mM of PTU and 5 mM of fructose was used
for further experiments. Control keratinocytes obtained from
abdominoplasty patients were treated with fructose and PTU indepen-
dently and in combination. We measured the percentage of live cells.
No signiﬁcant changes were seen between the treated and untreated
control cells.
3.1. Improved K1 and K10 transcript levels in cultured psoriatic keratinocytes
after treatment with fructose and PTU
Poor differentiation in psoriatic keratinocytes was apparent from the
decreased K1 & K10 levels compared to keratinocytes from control sam-
ples (0.56 and 0.60 fold change respectively, p b 0.05) (Fig. 2). Fructose
treatment to psoriatic keratinocytes improved K1 and K10 levels by 1.66
and 2.5 fold respectively (p b 0.001). PTU treatment was also very effec-
tive in improving differentiation in psoriatic keratinocytes and the fold
change for K1 and K10 were 2.04 and 2.79 respectively (p b 0.001). Con-
trol keratinocytes obtained from abdominoplasty patients were treated
with fructose and PTU independently and in combination. We measured
the mRNA expression of K1 and K10. No signiﬁcant changes were seen
between the treated and untreated control cells.
3.2. SIRT1 levels in cultured psoriatic keratinocytes was increased by fruc-
tose but not by PTU
The effect of PTU and fructose on SIRT1 mRNA transcript levels in
psoriatic keratinocytes was studied by Real time PCR (Fig. 3). SIRT1
mRNA level was found to be 0.56 fold lesser in psoriatic keratinocytes
Fig. 1. A.MTT Assay showing percentage of viable cells in control, untreated, 2–10 mM
PTU treated psoriatic keratinocytes. All values are expressed as mean ± SD. B. MTT
Assay showing percentage of viable cells in control, untreated, 1–20 mM fructose
treated psoriatic keratinocytes. All values are expressed as mean ± SD.
Fig. 3. Fold change of SIRT1 transcripts in control, psoriatic keratinocytes, fructose treated
psoriatic keratinocytes and PTU treated psoriatic keratinocytes. All values are expressed as
mean± SD. ‘a’ denotes psoriasis compared to control, ‘b’ denotes psoriasis+ fructose and
psoriasis+ PTU compared to psoriasis. ‘⁎’denotes p b 0.05, ‘$’denotes p b 0.001, ‘NS’ denotes
non-signiﬁcant.
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was brought about by fructose treatment to psoriatic keratinocytes in
SIRT1 levels is 1.75 (p b 0.001); there were no signiﬁcant changes in
SIRT1 mRNA transcript levels in psoriatic keratinocytes upon PTU
treatment.Fig. 2. Fold change of K1 and K10 transcripts in control, psoriatic keratinocytes, fructose
treated psoriatic keratinocytes and PTU treated psoriatic keratinocytes. All values are
expressed as mean ± SD. ‘a’ denotes psoriasis compared to control, ‘b’ denotes
psoriasis + fructose and psoriasis + PTU compared to psoriasis. ‘⁎’denotes p b 0.05,
‘$’denotes p b 0.001.Western blot analysis showed similar pattern of SIRT1 protein levels
in psoriatic keratinocytes before and after treatment with PTU and fruc-
tose (Fig. 4A). Elevated SIRT1 protein level is evident in the fructose treat-
ed psoriatic keratinocytes (p b 0.001) compared to untreated cells as
measured by densitometry analysis (Image J software) whereas PTU
treatment did not elevate SIRT1 protein levels signiﬁcantly (Fig. 4B). Con-
trol keratinocytes obtained from abdominoplasty patients were treated
with fructose and PTU independently and in combination. We measured
the mRNA expression and protein levels of SIRT1. No signiﬁcant changes
were seen between the treated and untreated control cells.4. Discussion
Several attempts have been made in the recent past to improve
differentiation in psoriatic keratinocytes that include NO donor,Fig. 4. A.Western blot showing SIRT1 protein levels in control, psoriatic keratinocytes,
fructose treated psoriatic keratinoctyes and PTU treated psoriatic keratinocytes. B
Relative densities of SIRT1 in control, psoriatic keratinocytes, fructose treated psoriatic
keratinocytes and PTU treated psoriatic keratinocytes. All values are expressed as
mean ± SD. ‘a’ denotes psoriasis compared to control, ‘b’ denotes psoriasis + fructose
and psoriasis + PTU compared to psoriasis. ‘⁎’denotes p b 0.05, ‘$’denotes p b 0.001, ‘NS’
denotes non-signiﬁcant.
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cognate ligands and delphinidin [12–15]. In this study, fructose and
PTU were used to improve differentiation in psoriatic keratinocytes.
In psoriatic keratinocytes, levels of K1 and K10 transcripts were sig-
niﬁcantly low compared to control samples. This is consistent with
previous reports which describe a characterized decrease in K1,
K10 in hyperproliferative epidermis [2,16].
Decreased SIRT1 levels is the primary reason for the diminished dif-
ferentiation in psoriasis. Conversely fructose treatment to psoriatic
keratinocytes resulted in increased SIRT1 levels (Fig. 2) and improved
K1, K10 transcript levels; PTU treatment did not produce a signiﬁcant
change in SIRT1 levels but managed to improve K1 and K10 levels.
When Blander et al. (2009) studied the effect of SIRT1 on differentiation
pattern in keratinocytes, they found that SIRT1 expression paralleled dif-
ferentiation marker levels and reduced keratinocyte proliferation rates
[7]. The quest for a new drug probably lead to the use of PTU in
treating psoriasis. Elias et al. postulated that this drug can potentially
reduce the cytokine signals that lead to keratinocyte proliferation
[17]. Halting of proliferation in psoriatic keratinocytes by PTU com-
mences differentiation. In our earlier study we reported that PTU
down regulated abnormal keratinocyte differentiation protein,
involucrin [11]. Presently we declare that PTU improves expression
of normal keratinocyte differentiation markers (K1/K10) conﬁrming
the mechanism of PTU and its clinical efﬁcacy in psoriasis treatment.
In addition PTU is said to promote differentiation of vascular smooth
muscle cells via PTEN induction [18].
The expression levels of keratin genes are ﬁne-tuned and appear to be
regulated by large number of transcription factors [19]. Important regula-
tory sites of these differentiation markers are found in the promoter re-
gions. Many keratin gene expression are regulated by transcription
factors AP1, AP2 and Sp1. AP-1 is an assembly of heterodimeric protein
complexes, including Jun family members namely c-Jun, JunB, JunD, and
fos family of transcription factors such as c-Fos, FosB, Fra-1, and Fra-2
[20]. The most common dimer in AP-1 signalling pathway is c-Jun/c-Jun
homodimers or c-Jun/c-Fos heterodimers whose transcriptional activity
is regulated by post translational modiﬁcation like acetylation [21]. The
acetylation of transcriptional factors alters the protein-DNA and protein-
protein interactions which are important regulatorymechanisms of tran-
scription [22].
Members of the AP-1 family were found to exhibit antagonistic ef-
fects. While c-Jun is a promoter of proliferation, JunB is a suppressor of
proliferation and promoter of differentiation [23]. Down regulation of
JunB could be the reason for the uncontrolled proliferation and poor dif-
ferentiation of keratinocytes in psoriasis [24]. It has been suggested that
SIRT1 directly inhibits the transcriptional activity of AP-1 by interacting
with the basic leucine zipper domains of c-Fos and c-Jun, the major
components of AP-1 [25]. The improved differentiation in psoriatic
keratinocytes in our results by fructose can be attributed to the im-
proved SIRT1 levels which might have suppressed c-Fos and c-Jun, ar-
resting proliferation but initiating differentiation. It has been reported
that SIRT1 over expression does not activate JunB in skeletal muscles.
Since, SIRT1 mediated effects are tissue speciﬁc, whether SIRT1 im-
proves JunB levels in keratinocytes is yet to be identiﬁed. Of equal im-
portance, PTU induced differentiation as conﬁrmed by improved K1
and K10 levels, followed a non-SIRT1 mechanism due to less or no
change in expression of SIRT1 in vitro. AP-2, a family of large DNA bind-
ing transcription factors also controls the balance between growth and
differentiation in the epidermis [26]. AP-2 controls the expression
of K10 via activation or repression of the c/ebpα, c/ebpβ, and ap-
2α gene promoters [27]. Further studies are warranted with
larger sample size on the role of SIRT1 in AP-2 regulated genes in dif-
ferentiation and proliferation factors in keratinocytes. In conclusion,
both fructose and PTU are able to induce differentiation in psoriatic
keratinocytes through SIRT-1 mediated and non-SIRT-1 mechanisms
respectively. Thus fructose and PTU can be used as adjunct in existing
therapies for psoriasis.Conﬂict of interest statement
The authors declare that there is no conﬂict of interest.
Compliance with ethics guidelines
This study has been performed in accordance with the ethical stan-
dards as laid down in the 1975 Declaration of Helsinki and its later
amendments or comparable ethical standards.
Transparency document
The Transparency document associated with this article can be
found, in online version.
Acknowledgement
This work was supported by Science and Engineering Research
Board (SERB), Department of Science and Technology, Government of
India. Grant No: [SR/FT/LS-125/2012].
References
[1] E. Fuchs, Epidermal differentiation: the bare essentials, J. Cell Biol. 111 (1990)
2807–2814 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
2116387&tool=pmcentrez&rendertype=abstract (accessed July 20, 2015).
[2] F. Bernerd, T. Magnaldo, M. Darmon, Delayed onset of epidermal differentiation in
psoriasis, J. Investig. Dermatol. 98 (1992) 902–910 (http://www.ncbi.nlm.nih.gov/
pubmed/1375620 (accessed August 19, 2015)).
[3] J. Cheng, A.J. Syder, Q.C. Yu, A. Letai, A.S. Paller, E. Fuchs, The genetic basis of
epidermolytic hyperkeratosis: a disorder of differentiation-speciﬁc epidermal kera-
tin genes, Cell 70 (1992) 811–819 (http://www.ncbi.nlm.nih.gov/pubmed/1381287
(accessed August 19, 2015)).
[4] J.M. Paramio, C. Segrelles, S. Ruiz, J.L. Jorcano, Inhibition of protein kinase B (PKB)
and PKCzeta mediates keratin K10-induced cell cycle arrest, Mol. Cell. Biol. 21
(2001) 7449–7459, http://dx.doi.org/10.1128/MCB.21.21.7449-7459.2001.
[5] P. Frost, G.D. Weinstein, E.J. Van Scott, The ichthyosiform dermatoses. II. Autoradio-
graphic studies of epidermal proliferation, J. Investig. Dermatol. 47 (1966) 561–567
(http://www.ncbi.nlm.nih.gov/pubmed/5957926 (accessed August 19, 2015)).
[6] J. Reichelt, G. Furstenberger, T.M. Magin, Loss of keratin 10 leads to mitogen-
activated protein kinase (MAPK) activation, increased keratinocyte turnover, and
decreased tumor formation in mice, J. Investig. Dermatol. 123 (2004) 973–981,
http://dx.doi.org/10.1111/j.0022-202X.2004.23426.x.
[7] G. Blander, A. Bhimavarapu, T. Mammone, D. Maes, K. Elliston, C. Reich, M.S. Matsui, L.
Guarente, J.J. Loureiro, SIRT1promotes differentiationof normal humankeratinocytes, J.
Investig. Dermatol. 129 (2009) 41–49, http://dx.doi.org/10.1038/jid.2008.179.
[8] K. Boniface, F.-X. Bernard, M. Garcia, A.L. Gurney, J.-C. Lecron, F. Morel, IL-22 inhibits
epidermal differentiation and induces proinﬂammatory gene expression and migra-
tion of human keratinocytes, J. Immunol. 174 (2005) 3695–3702 (http://www.ncbi.
nlm.nih.gov/pubmed/15749908 (accessed May 10, 2015)).
[9] J.B. Pillai, M. Chen, S.B. Rajamohan, S. Samant, V.B. Pillai, M. Gupta, M.P. Gupta, Acti-
vation of SIRT1, a class III histone deacetylase, contributes to fructose feeding-
mediated induction of the alpha-myosin heavy chain expression, Am. J. Physiol.
Heart Circ. Physiol. 294 (2008) H1388–H1397, http://dx.doi.org/10.1152/ajpheart.
01339.2007.
[10] H. Malligarjunan, P. Gnanaraj, S. Subramanian, T. Elango, H. Dayalan, Clinical efﬁcacy
of propylthiouracil and its inﬂuence on prolactin in psoriatic patients, Clin. Biochem.
44 (2011) 1209–1213, http://dx.doi.org/10.1016/j.clinbiochem.2011.07.009.
[11] P. Gnanaraj, H. Dayalan, T. Elango, H. Malligarjunan, V. Raghavan, R. Rao, Downreg-
ulation of involucrin in psoriatic lesions following therapy with propylthiouracil, an
anti-thyroid thioureylene: immunohistochemistry and gene expression analysis,
Int. J. Dermatol. 54 (2015) 302–306, http://dx.doi.org/10.1111/ijd.12565.
[12] S. Abeyakirthi, M. Mowbray, N. Bredenkamp, L. van Overloop, L. Declercq, P.J. Davis,
M.S. Matsui, R.B. Weller, Arginase is overactive in psoriatic skin, Br. J. Dermatol. 163
(2010) 193–196, http://dx.doi.org/10.1111/j.1365-2133.2010.09766.x.
[13] I. Helwa, R. Patel, P. Karempelis, I. Kaddour-Djebbar, V. Choudhary, W.B. Bollag, The
antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative,
and anti-inﬂammatory effects on keratinocytes, J. Pharmacol. Exp. Ther. 352
(2015) 90–97, http://dx.doi.org/10.1124/jpet.114.218818.
[14] Y. Ramot, A. Mastrofrancesco, E. Camera, P. Desreumaux, R. Paus, M. Picardo, The
role of PPARγ-mediated signalling in skin biology and pathology: new targets and
opportunities for clinical dermatology, Exp. Dermatol. 24 (2015) 245–251, http://
dx.doi.org/10.1111/exd.12647.
[15] J.C. Chamcheu, H.C. Pal, I.A. Siddiqui, V.M. Adhami, S. Ayehunie, B.T. Boylan, F.K.
Noubissi, N. Khan, D.N. Syed, C.A. Elmets, G.S. Wood, F. Afaq, H. Mukhtar,
Prodifferentiation, anti-inﬂammatory and antiproliferative effects of delphinidin, a
dietary anthocyanidin, in a full-thickness three-dimensional reconstituted human
skin model of psoriasis, Skin Pharmacol. Physiol. 28 (2015) 177–188, http://dx.
doi.org/10.1159/000368445.
86 S. Arul et al. / BBA Clinical 6 (2016) 82–86[16] A. Ishida-Yamamoto, T. Senshu, H. Takahashi, K. Akiyama, K. Nomura, H. Iizuka, De-
creased deiminated keratin K1 in psoriatic hyperproliferative epidermis, J. Investig.
Dermatol. 114 (2000) 701–705, http://dx.doi.org/10.1046/j.1523-1747.2000.00936.x.
[17] A.N. Elias, V.S. Nanda, R.J. Barr, Effect of PTU on IL-12 and IL-10 in psoriasis, J. Drugs
Dermatol. 2 (2003) 645–648 (http://www.ncbi.nlm.nih.gov/pubmed/14711144
(accessed June 28, 2016)).
[18] W.-J. Chen, J.-H.S. Pang, K.-H. Lin, D.-Y. Lee, L.-A. Hsu, C.-T. Kuo, Propylthiouracil, in-
dependent of its antithyroid effect, promotes vascular smooth muscle cells differen-
tiation via PTEN induction, Basic Res. Cardiol. 105 (2010) 19–28, http://dx.doi.org/
10.1007/s00395-009-0045-z.
[19] Intermediate Filaments, Springer US, Boston, MA, 2006 http://dx.doi.org/10.1007/0-
387-33781-4.
[20] V.C. Foletta, Transcription factor AP-1, and the role of Fra-2, Immunol. Cell Biol. 74
(1996) 121–133, http://dx.doi.org/10.1038/icb.1996.17.
[21] R.G. Vries, M. Prudenziati, C. Zwartjes, M. Verlaan, E. Kalkhoven, A. Zantema, A speciﬁc
lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by
p300, EMBO J. 20 (2001) 6095–6103, http://dx.doi.org/10.1093/emboj/20.21.6095.
[22] J. Luo,M. Li, Y. Tang,M. Laszkowska, R.G. Roeder,W.Gu, Acetylation of p53 augments its
site-speciﬁc DNA binding both in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A. 101
(2004) 2259–2264 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
356938&tool=pmcentrez&rendertype=abstract (accessed August 19, 2015)).[23] E. Shaulian, M. Karin, AP-1 in cell proliferation and survival, Oncogene 20 (2001)
2390–2400, http://dx.doi.org/10.1038/sj.onc.1204383.
[24] R. Zenz, E.F. Wagner, Jun signalling in the epidermis: from developmental defects to
psoriasis and skin tumors, Int. J. Biochem. Cell Biol. 38 (2006) 1043–1049, http://dx.
doi.org/10.1016/j.biocel.2005.11.011.
[25] R. Zhang, H.-Z. Chen, J.-J. Liu, Y.-Y. Jia, Z.-Q. Zhang, R.-F. Yang, Y. Zhang, J. Xu, Y.-S.
Wei, D.-P. Liu, C.-C. Liang, SIRT1 suppresses activator protein-1 transcriptional activ-
ity and cyclooxygenase-2 expression in macrophages, J. Biol. Chem. 285 (2010)
7097–7110, http://dx.doi.org/10.1074/jbc.M109.038604.
[26] C.K. Kaufman, S. Sinha, D. Bolotin, J. Fan, E. Fuchs, Dissection of a complex enhancer
element: maintenance of keratinocyte speciﬁcity but loss of differentiation speciﬁc-
ity, Mol. Cell. Biol. 22 (2002) 4293–4308 (http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=133856&tool=pmcentrez&rendertype=abstract
(accessed August 19, 2015)).
[27] E.V. Maytin, J.C. Lin, R. Krishnamurthy, N. Batchvarova, D. Ron, P.J. Mitchell, J.F.
Habener, Keratin 10 gene expression during differentiation of mouse epidermis re-
quires transcription factors C/EBP and AP-2, Dev. Biol. 216 (1999) 164–181, http://
dx.doi.org/10.1006/dbio.1999.9460.
